Vimentin Antibody (J144): sc-53464

Vimentin Antibody (J144) is a mouse monoclonal IgM antibody raised against human rhabdomyosarcoma cell line JR1, targeting vimentin, a crucial intermediate filament protein that forms an essential part of the cellular scaffolding in mesenchymal cells. Vimentin mouse monoclonal antibody (J144) recognizes an epitope within vimentin and demonstrates effectiveness in immunohistochemistry, immunofluorescence, immunoprecipitation, and Western blotting applications. Anti-vimentin monoclonal antibody (J144) is available in non-conjugated form and conjugated forms including horseradish peroxidase and fluorescein isothiocyanate, offering versatility for diverse experimental approaches. Understanding vimentin′s regulation reveals a sophisticated network of post-translational modifications that fine-tune vimentin′s cellular functions. For example, during cell division, specific kinases add phosphate groups to vimentin at Ser38 and Ser55, triggering a carefully orchestrated disassembly and reorganization of vimentin filaments necessary for proper mitosis. Similarly, acetylation serves as a molecular switch controlling vimentin stability and assembly properties, particularly when cells face stressful conditions. The addition of ubiquitin molecules to vimentin marks this protein for degradation, providing cells with a mechanism to rapidly adjust their shape and movement capabilities in response to changing environments. Beyond these modifications, vimentin participates in crucial protein partnerships that extend its cellular influence. By interacting with desmin, vimentin helps create a robust structural framework in muscle cells, while vimentin′s partnership with β-catenin connects the cytoskeleton to cell adhesion systems and signaling networks involved in cancer development. Through these various modifications and interactions, vimentin maintains cellular architecture, provides essential mechanical support, and enables critical processes such as cell migration - functions that become particularly significant during epithelial-to-mesenchymal transition (EMT) and cancer metastasis. Vimentin (J144) antibody serves as an invaluable tool for investigating these complex regulatory mechanisms in cancer research, EMT studies, and cytoskeletal dynamics.

The preferred Vimentin antibody is Vimentin Antibody (V9): sc-6260.